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Introduction 
Cloning and sequence analysis of cDNAs and DNA 
fragments from genomic libraries has led to a dramatic 
increase in understanding of the glucagon-related 
peptides in recent years. The primary structure of the 
biosynthetic precursor of glucagon (preproglucagon) 
has been elucidated. The complex structural connec- 
tions between the multiple molecular forms of the 
glucagon-like peptides in tissues and in the circulation 
have been determined [ 1,2]. 
Mammalian proglucagon consists of 160 amino acid 
residues and is synthesized in the islets of Langerhans, 
intestine and brain. An exciting recent finding is that in 
addition to glucagon the preproglucagon gene in 
mammals encodes two additional peptides with struc- 
tural similarity to glucagon, termed glucagon-like 
peptide-1 and -2 (GLP-I and GLP-2). The truncated 
form of GLP-1, GLP-1(7-36) amide, which is secreted 
by the mammalian intestine, strongly stimulates insu- 
lin secretion and inhibits gastric acid secretion. This 
review focuses mainly on the truncated form of GLP-1. 
since a rapidly increasing number of reports indicate a 
remarkable interest of investigators in this particular 
hormone, which actually fulfills the classical role of an 
‘enterogastrone’ and ‘incretin’ hormone. The purpose 
here is to describe what is known so far about the 
origin, processing, organ distribution and actions of 
this peptide and to search for promising future direc- 
tions of further investigations. 
Origin and processing of pre-proglucagon-derived 
peptides 
Probably only a single copy of the pre-proglucagon 
gene is contained in the human genome. This gene 
comprises five introns and six exons [3,4,5]. It has been 
shown that preproglucagon messenger RNA from 
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pancreas and intestine are identical [6,7] but the 
pathway of post-translational processing of the pri- 
mary transcript differs markedly in the two tissues [I]. 
Mammalian proglucagon exhibits several pairs of 
dibasic amino acid residues which are potential pro- 
cessing sites for enzymes [8]. In the A-cell of the 
pancreas proglucagon is predominantly processed into 
proglucagon( 1-30) (also called glicentin-related pan- 
creatic peptide (GRPP) [9]), proglucagon(33-61) 
which is identical with glucagon, the hexapeptide 
proglucagon(64-69) [ 101 and the carboxy-terminal 
fragment proglucagon(72-l58) [ 1 I]. The carboxy- 
terminal fragment contains the sequences of glucagon- 
like peptide-I and glucagon-like peptide-2 but is not 
further processed in the pancreas [I 13 (Fig. 1). 
In the L-cell of the gut proglucagon is predomi- 
nantly processed to proglucagon( 1-69) also called 
glicentin [12], oxyntomodulin (proglucagon(33-69)) 
[ 131, glucagon-like peptide-I (GLP- 1; proglucagon 
(72-1 08)) and glucagon-like peptide-2 (GLP-2; pro- 
glucagon(126-158)) [6,14]. GLP-l(1-37) is further 
processed to GLP-l(7-37) [I] which is the predomi- 
nant form of GLP- 1 in the gut of human [ 141, rat [6,16] 
and pig [ 171. 
Recently, it was demonstrated that the truncated 
form of pig and human GLP- 1 contains an a-amidated 
carboxy-terminal amino acid residue [15]. It is interest- 
ing that the amino acid sequence of GLP-1 closely 
resembles that of glucagon; 14 of 19 amino acid 
residues are identical to glucagon when position 7 
(histidine) of GLP-I is aligned with position 1 (histi- 
dine) of glucagon. It is believed that histidine at 
position 7 of GLP-1 as the free N-terminal amino acid 
is of special importance in GLP- 1’s insulinotropic 
activity and probably in its glucagon-inhibiting acti- 
vity, and that C-terminal amino acids are less impor- 
tant for these effects [18,19]. 
The sequence of GLP-I is identical in various 
different mammals like rat, hamster, guinea-pig, 
bovine and man [1,2,20]. Such strong conservation of 
the peptide sequence during evolution points to an 
important biological role for GLP-I . 
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Figure 1. Schematic figure of the glucagon gene with its six exons (1-6) and the proglucagon mRNA containing the proglucagon 
derived peptides. 5’-UT, 5’-untranslated sequences; 3’-UT, 3‘-untranslated sequences; S ,  signal peptide; GLP-1, glucagon-like 
peptide-I; GLP-2, glucagon-like peptide-2; MPGF, major proglucagon fragment; Oxy, oxyntomodulin (from Drucker DJ. 
Pancreas 1990;5:484-488). 
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Figure 2. Tissue specific processing of proglucagon in pancreas and intestine (AA = amino acid). 
Specific receptors for GLP-l(7-36) amide 
The discovery that insulin-producing cells contain 
specific binding sites for GLP- 1(7-36) amide supports 
the assumption that the truncated form of GLP-1 may 
be a gastrointestinal hormone of physiological signi- 
ficance [21]. Whereas no binding sites could be demon- 
strated on enterocytes from pig jejunum [21], highly 
specific binding of ‘251-labelled GLP- 1(7-36) amide to 
rat insulinoma derived RINmSF cells was found [21] 
(Fig. 2). Scatchard analysis of the binding data 
revealed the presence of a single class of binding sites 
with a dissociation constant (Kd) of 2.04 x lo-’’ M. In 
cross-linking studies with RINmSF cell membranes 
the molecular weight of the binding protein for GLP- 
l(7-36) amide was determined to be 63 000 [22]. Since 
no change in the mobility of the receptor band was 
observed under reducing conditions it was suggested 
that the binding protein in the receptor is not attached 
to other subunits via disulphide bonds [22]. 
Binding of the truncated GLP-l(7-36) amide 
resulted in a dose-dependent increase of CAMP pro- 
duction [21], which suggests that the binding site is a 
receptor linked to a functional response and not, for 
example, a site linked to a system of proteolytic 
inactivation. Binding of GLP-l(7-36) amide to 
RINmSF cell membranes was decreased by the intro- 
duction of guanine nucleotides to the assay system. 
This effect was due to a decrease of the receptor 
affinity, whereas the receptor number remained 
unchanged [23]. In contrast to fuel and non-fuel 
secretagogues, GLP-l(7-36) amide did not cause a 
depolarization of membrane potential or changes in 
cytosolic free calcium levels in RINmSF cells [23]. 
These data suggest that the action of the peptide is 
mediated by the adenylate cyclase system. This as- 
sumption is supported by the finding that GLP-l(7- 
37) also increased CAMP levels in another insulin- 
producing cell line [24]. An involvement of the inositol 
1,4,5trisphosphate pathway or an activation of pro- 
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Figure 3. Inhibition of binding of '2sI-labelled glucagon-like peptide- 
l(7-36) amide to rat RINmSF cells by GLP-l(7-36) amide, GLP-1 
(1-36) amide, glucagon and GLP-2. Incubations were carried out for 
30 min at 37'C at a cell concentration equivalent to 20 pg DNA/tube. 
Data points show meansf SEM for at  least six experiments. Specific 
binding is defined as the total binding of radioactivity minus the 
binding in the presence of 1 pmol GLP-l(7-36) amide/l (from Coke 
R, Conlon JM. J Endocrinol 1988;116:357-362). 
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tein kinase C in the post-receptor signalling after GLP- 
l(7-36) amide binding appears to be unlikely. 
In a recent study, receptors for GLP-l(7-37) have 
been identified on isolated rat gastric glands [25]. 
Scatchard analysis revealed the presence of a single 
class of binding sites with a Kd of 4.4 x M. 
Binding of truncated GLP-I resulted in an increase of 
cAMP formation with an of 1.6 x 1O-Io  M. These 
data demonstrate that the receptors on gastric glands 
are similar to the receptors which were identified on rat 
insulinoma cells. Recently, we characterized receptors 
for GLP-l(7-36) amide on rat lung membranes [26]. 
Scatchard analysis showed the presence of a single 
class of binding sites with a Kd of 1.67 x M. The 
binding affinity was 10 times less compared to the 
receptors on RINmSF cells ( 1 . 6 7 ~  M us 
0.204 x M). In contrast to our results with 
RINm5F cells, we found that VIP and PHI were more 
potent in displacing '251-labelled GLP- 1(7-36) amide 
from the rat lung receptors than other proglucagon- 
derived peptides except GLP- I(7-36) amide itself. The 
order of potency was GLP-i(7-36) amide>VIP> 
PHI > GLP-I( 1-36) amide > glucagon and GLP-2 
[26]. Binding of 1251-labelled GLP-l(7-36) amide to rat 
lung receptors was inhibited by guanine nucleotides, 
suggesting that these receptors similarly to GLP-1 
(7-36) amide receptors on RINmSF cells and gastric 
glands are coupled to the adenylate cyclase system [26]. 
Additional data have been published which demon- 
strate the existence of high affinity receptors for GLP- 
l(7-36) amide in rat brain [27]. Again, binding of the 
peptide resulted in an increased cAMP production 
Up to now, the receptor for GLP-l(7-36) amide has 
~ 7 1 .  
not been purified to an extent which would allow 
sequencing and eventually cloning. It would be impor- 
tant to raise specific antibodies against the receptor 
protein, which would, for example, allow in tiitlo 
immunoneutralization studies to prove the physio- 
logical effects of the peptide. 
Internalization of GLP-1(7-36) amide 
Receptor-mediated endocytosis appears to be a 
general mechanism by which cells internalize hor- 
mones after initial cell-surface binding. It was demon- 
strated that after binding to RINmSF cells GLP-l(7- 
36) amide is internalized and degraded intracellularly . 
Chloroquine was shown to inhibit the intracellular 
degradation and to delay the release of the degradation 
products [28] suggesting that the cleavage of the 
internalized peptide is facilitated by lysosomal degra- 
dation. It remains to be elucidated whether GLP-1(7- 
36) amide or a degradation product of the peptide has 
any effect on intracellular metabolism. Furthermore, it 
has not yet been proven whether the GLP-I-receptor 
undergoes internalization and consecutive degrada- 
tion or recycling, another reason to generate anti- 
bodies which are directed against receptor protein. 
GLP-1 and endocrine pancreas 
( 1 )  GLP-1-like immunoreactiuity ( IR)  in the pancreas 
GLP-1-like IR was identified in the pancreas by 
radioimmunoassay and immunocytochemistry using 
polyclonal antibodies against GLP- 1 (1 - 19) [29,30], 
GLP-1(1-37)/(1-36) amide [28-321 and monoclonal 
antibodies against GLP-l(1-36) amide [32]. GLP-I- 
like IR coexists with glucagon-like IR in the marginal 
zone of pancreatic A cells [29,30,32,33]. Analysis of 
pancreatic extracts showed that in human and pig 
pancreas most of the GLP-1-like IR has a molecular 
weight of 10 kDa [14,29,31]. This is in accordance with 
Patzelt & Schiltz, who reported preproglucagon to be 
processed to glucagon and a carboxyterminal frag- 
ment of 10 kDa molecular weight [l 11. In gel filtration 
of rat pancreatic extracts Manaka et al. [32] identified 
the major peak with a molecular weight of 4 2  kDa in a 
position identical to synthetic GLP-l(1-37) as has 
similarly been shown in cattle in a previous study [36]. 
This difference is perhaps due to species-specific 
proglucagon processing in the pancreas. 
( 2 )  GLP-1-like immunoreactivity ( I R )  released from 
the pancreas 
GLP-1 -like IR is co-released with glucagon-like IR 
from the pancreas in response to arginine stimulation. 
In human and pig pancreas the majority of the GLP-I - 
like IR released upon arginine stimulation has an MW 
of 10 kDa while in rat pancreas the 4.2-kDa form 
predominates [ 14,32,36,37]. Although some GLP-1- 
like material is released from the endocrine pancreas 
by far the most originates from the gut. 
138 R. GOKE et al. 
6.7 mM Glc + GLP-1(7-36)amide 
2.8mM G l c .  I 
I I 
15 30 45 60 
t [ rn in )  
Figure 4. Stimulation of insulin release from perfused rat pancreas by GLP-1(7-36) amide. Isolated pancreas was perfused in the 
absence (0) and presence of 0.05 nM (0, 0.5 nM (A), and 5 n M  (0) GLP-l(7-36) amide in the perfusate. Data points show 
means+SD of six experiments (from Coke R, Fehmann HC, Richter G ,  Trautmann M, Coke B. Pancreas 1989;4:668-673). 
( 3 )  Effects of GLP-I on the endocrine pancreas 
Initial studies did not demonstrate any biological 
activity of the peptide. GLP-l(1-36) amide did not 
alter blood glucose or insulin levels in fasted canines 
[38]. Schmidt, Siege1 & Creutzfeldt obtained a weak 
stimulatory effect on insulin secretion in isolated rat 
pancreatic islets using supraphysiological concentra- 
tions of GLP-l(1-36) amide [39], while GLP-l(1-36) 
amide had no insulinotropic effect in the isolated 
perfused pig pancreas as shown by Orskov, Holst, 
Knuhtsen, Baldissera, Poulsen & Vagn Nielsen [14]. In 
obese hyperglycaemic mice, Bailey & Flatt found a 
very small insulin-releasing effect of GLP- 1( 1-37) with 
no change of the blood glucose levels (40). 
A ‘break-through’ in this discussion about a possible 
physiological role for GLP-I was achieved by 
Drucker, Philippe, Mojsov, Chick & Habener in a later 
study which reported that not GLP-l(1-37), but the 
truncated form of this peptide potently increases 
CAMP levels, insulin mRNA transcripts, and insulin 
release in cultured rat insulinoma cells (RIN 1046-36). 
These findings were the first indication that the 
truncated peptide, GLP- l(7-36) amide, is the biologi- 
cally active form [24]. This assumption was confirmed 
by others who demonstrated a strong insulinotropic 
effect of GLP- 1(7-37) and GLP- 1(7-36) amide which 
were equipotent [ 17,411. 
In the isolated perfused pig pancreas in the presence 
of 7 mM glucose, GLP-l(7-36) amide at a concen- 
tration of lo-’’ M induced a 1.4-fold increase, and at 
M a 2.3-fold increase of insulin release. Arterial 
infusion and adjustment to a level of 10 - l o  M GLP- 1 
(7-37), resulted in an 2-fold increase, whereas a M 
concentration resulted in a 4-fold increase of the 
insulin release [17]. In the isolated perfused rat pan- 
creas in the presence of 6.6 mM glucose, GLP- l(7-37) 
at a concentration of 5 x lo-”  M led to a 3-10-fold 
elevation of insulin secretion [41]. No effect on insulin 
secretion was found with GLP-I( 1-37). Additional 
studies confirmed these observations showing a strong 
insulinotropic effect of GLP- 1(7-36) amide on insulin 
secretion [42,43,44,45] (Fig. 3). Studies in man demon- 
strated that circulating GLP- l(7-36) amide levels rose 
after oral glucose and after a meal. Infusion of the 
peptide in doses mimicking post-prandial concentra- 
tions resulted in a significant rise in insulin concentra- 
tions and a fall in blood glucose [46]. In this context it is 
of interest to mention that for a similar effect on 
glucose-stimulated insulin secretion the effective con- 
centration of GLP-l(7-36) amide was reported to be as 
low as one-tenth of that of GIP [43], the strongest 
incretin candidate up to recently, which indicates that 
GLP-l(7-36) amide has a greater insulinotropic effect 
than GIP. Taken together, GLP- 1(7-36) amide fulfills 
the classic conditions that allow its identification as an 
incretin hormone [47,48]: it is released from the gut by 
nutrients, especially carbohydrates, and it stimulates 
insulin secretion in the presence of elevated blood 
glucose levels. 
Studies in man revealed that GLP- l(7-36) amide 
has not only an insulinotropic but also a glucagon- 
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suppressing effect [46]. This was confirmed by experi- 
ments with isolated perfused pig pancreas in which 
GLP-1(7-36) amide at a concentration of M 
inhibited glucagon secretion by 50% and at M by 
70-80% [42]. Similar results were obtained in studies 
with isolated perfused rat and canine pancreas [49,50]. 
Truncated GLP- l(7-36) amide significantly 
increased somatostatin secretion from the isolated 
perfused pig pancreas. At lop9 M GLP-1(7-36) amide 
somatostatin release was more than doubled [42] 
compared to controls. At present it is unclear whether 
the glucagon-suppressing effect of the truncated 
GLP-1 is a direct result of the peptide or whether this 
effect is mediated by somatostatin, since somatostatin 
was reported to be a mediator of the suppression of 
glucagon during hyperglycaemia [5 I]. This latter 
explanation is supported by a recent report by D'Ales- 
sio, Fujimoto & Ensick which demonstrated in islet cell 
monolayer cultures from rat pancreas that GLP-l(7- 
36) amide increased somatostatin release by 40% but 
left glucagon release unaffected [52]. It is possible that 
in intact islets the paracrine effects of somatostatin and 
insulin may inhibit glucagon release after GLP- l(7-36) 
amide exposure. 
Recent studies compared the effects of various N- 
terminal and C-terminal fragment peptides of 
GLP- l(7-36) amide on insulin and glucagon release 
from the isolated perfused rat pancreas as well as on 
cAMP formation in the PTCl cell line [18,19]. Con- 
cerning the N-terminal portion, GLP- l(7-37) amide 
was proved to be a potent insulinotropic secretagogue 
while GLP-I ( I  -37) amide, GLP-l(6-37) amide and 
GLP- l(8-37) amide showed no effect on insulin 
release. Concerning the C-terminal portion, GLP-1 
(7-37) amide, GLP-1(7-36) amide and GLP-l(7-37) 
showed similar potency in stimulating the insulin 
release while GLP- l(7-34) and GLP- 1(7-35) were less 
potent and CLP-l(7-20) and GLP-l(7-33) had no 
effect. Similar results were found when the cAMP 
formation in the PTCl cell line was studied. Glucagon 
release was suppressed by GLP- 1 (7-37), GLP- l(7-37) 
amide and GLP- l(7-36) amide at concentrations in 
which these peptides stimulated insulin release (1  and 
10 nM) while other fragments had no effect. These 
results suggest that histidine at  position 7 of GLP-1 
(7-37) is important for the stimulation of cAMP 
production, insulin release, and inhibition of glucagon 
release. Furthermore, the three C-terminal amino 
acids as well as the C-terminal amidation seem to be 
less important for these effects. It would be of interest 
to employ a sensitive and specific antibody against 
GLP- l(7-36) amide to induce an experimental GLP- 
l(7-36) amide deficiency in uiuo. This could help to 
determine the importance of the hormone in the 
control of insulin secretion. Unfortunately, a first 
approach using an antibody against the precursor 
molecule GLP-1 revealed rather ambiguous results 
[53]. Whereas the insulinotropic effect of exogenous 
GLP-1(7-36) amide was reduced, injection of GLP-1 
antiserum did not decrease insulin release after an oral 
glucose load in rats [53]. These experiments have to be 
repeated using specific antibodies directed against the 
truncated form of the peptide. 
( 4 )  Interaction of GLP-1(7-36) amide with other 
hormones 
Accumulating evidence suggests that several intestinal 
hormones are involved in the regulation of the entero- 
insulinar-axis [48]. Furthermore, it is likely that vari- 
ous incretin factors act in concert to modulate insulin 
release. Zawalich reported that a combination of GIP 
and cholecystokinin (CCK) leads to a markedly 
amplified glucose-induced insulin response in peri- 
fused rat islets [54] and Ahren, Hedner & Lundquist 
demonstrated a strong insulinotropic effect of GIP and 
CCK-8 injected together in low doses in mice [ 5 5 ] .  
From these findings, it was of interest to study the 
interaction of GLP-l(7-36) amide, CCK-8 and GIP on 
insulin secretion. The GLP-l(7-36) amide (5 x 1O-Io  
M) stimulated, glucose-induced (6.7 mM) insulin release 
from the perfused rat pancreas was potentiated by 
CCK-8 (maximal effect at  5 x lo-" M) [56] (Fig. 4). 
GLP-l(7-36) amide (5 x lo-'' M) and GTP (maximal 
effect at  lod9 M) exerted an additive synergistic effect 
upon glucose-induced insulin release [57] (Fig. 4). 
Since the effect of GLP-l(7-36) amide is mediated by 
the adenylate cyclase system [23] the potentiation of 
the GLP-1 effect by CCK was explained by an 
interaction of different second messenger systems [56] 
as was suggested in the case of GIP and CCK [54]. 
Since both GLP-l(7-36) amide and GIP act via the 
adenylate cyclase system a combination of both 
revealed an additive synergistic effect which was only 
obtained when submaximal effective hormone concen- 
trations were utilized [57]. 
Another exciting possibility for an interaction of 
gastrointestinal hormones in regulating insulin secre- 
tion was reported from experiments in which different 
incretin candidates were investigated for their ability 
to sensitize the endocrine pancreas against subsequent 
stimulation by another stimulus. A short lasting 
preinfusion of GLP-l(7-36) amide, GIP, and CCK 
induced an augmented insulin secretion in response to 
subsequent glucose stimulation [58]. 
It has been shown that the GLP-l(7-36) amide 
stimulated cAMP production in RINm5F cells is 
partially inhibited by somatostatin- 14 [45]. Further- 
more, somatostatin lowered the glucose-induced, 
GLP-l(7-36) amide potentiated insulin secretion [46]. 
The intracellular mechanism of this inhibitory action 
of somatostatin on the insulin release has yet not been 
fully explained. However, due to the observation that 
somatostatin inhibits secretagogue-stimulated cAMP 
accumulation in the exocrine pancreas [59] it seems 
likely that the inhibitory action of somatostatin on the 
glucose-induced, GLP- 1-potentiated insulin release is 
at least partly related to a regulation of the adenylate 
cyclase system. 
It has been demonstrated that in RINmSF cells, 
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Figure 5. Effect of gastric inhibitory peptide (GIP) (upper panel) and cholecystokinin-8 (CCK-8) (lower panel) on glucose 
(6.7 mM)-induced and GLP-l(7-36) amide (0.5 nM)-potentiated insulin secretion from the isolated perfused rat pancreas. Upper 
panel: (I) glucose+GLP-1(7-36) amide; (11) glucose+GLP-1(7-36) amidef GIP (0.1 nM); (111) glucose+ GLP-I (7-36) 
amide+GIP (1 mM); (IV) glucose+GLP-1(7-36) amide+GIP (10 nM) (from Fehmann HC, Goke B, Goke R, Trautmann ME, 
Arnold R. FEBS Lett 1989;252:109-112. Lower panel: (1) glucose; (11) glucose+GLP-1(7-36) amide; (111) glucose+GLP-1(7-36) 
amide+CCK-8 (20 PM); (IV) glucose+GLP-1(7-36) amide+CCK-8 (100 PM); (V) glucosef GLP-l(7-36) amide+CCK-8 (50 
PM) (from Fehmann HC, Goke B, Weber V, Goke R, Trautmann ME, Richter G, Arnold R. Pancreas 1990;5:361 365). Data 
points show means f SEM of at least six experiments. 
pretreated with dexamethasone for up to 72 h, binding 
of GLP-l(7-36) amide was markedly reduced. Further 
analysis of the binding data revealed a reduction of the 
receptor number while the receptor affinity remained 
unchanged [60]. From these results it was speculated 
that the effect of GLP-l(7-36) amide receptors induced 
by glucocorticoids could contribute to the impaired 
glucose tolerance in glucocorticoid-induced diabetes 
[60]. However, this suggestion remains rather specula- 
tive and needs further confirmation. 
Up to now, clinical studies considering physiological 
and pathophysiological implications of GLP-I (7-36) 
amide are clearly lacking. Although initial human 
studies [46] indicated that GLP-1(7-36) amide is a 
physiological incretin in man, these findings have to be 
corroborated and extended to patients suffering from 
different forms of diabetes mellitus before clear conclu- 
sions can be drawn. Results are expected in the near 
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future since several groups are currently developing or 
validating sensitive and reliable radioimmunoassay 
systems. 
GLP-1 and the exocrine pancreas 
Studies with isolated rat pancreatic acini showed that 
neither GLP-l(7-36) amide [56] nor any of the proglu- 
cagon-derived peptides [6 I] have an effect on basal and 
cholecystokinin-stimulated amylase release from iso- 
lated rat acini. No information is available on the 
effect on pancreatic secretion under other conditions. 
GLP-1 and liver 
Searching for possible effects of GLP-1 on glucose 
metabolism Ghiglione et al. and Shimizu, Hirota, 
Ohboshi & Shima failed to demonstrate specific 
binding sites on rat liver membranes [62,63]. Further- 
more, GLP-l(7-36) amide did not interact with gluca- 
gon receptors, in accordance to a previous study 
published by Hoosein & Gurd [64]. GLP-l(1-36) 
amide did not alter the cAMP level in the presence or 
absence of glucagon [62] and had no effect on glyco- 
genolysis in cultured rat hepatocytes [63]. 
It is possible to explain the failure of GLP-1 to 
influence hepatic glucose metabolism by the fact that 
the precursor molecule GLP-1 was used instead of the 
truncated peptide. However, in studies with GLP-1 
(7-36) amide no effect on glucose metabolism was 
found in the isolated perfused rat liver (KH Beckh, 
Marburg; personal communication). In contrast, fish 
GLPs were reported to stimulate glycogenolysis, glu- 
coneogenesis and lipolysis [65-691. These actions were 
found to be very variable depending on season and fish 
species (66-70). As known so far, preproglucagon- 
derived peptides in several species of elasmobranch, 
holostean and teleostean fishes contain only one GLP 
corresponding mainly to GLP-l(7-37) [66,71]. Inter- 
estingly, the activation of gluconeogenesis in these 
studies was not accompanied by an increase of cAMP 
formation. Since no specific binding sites were identi- 
fied on liver membranes, the authors postulated the 
presence of intracellular recognition sites for GLPs 
[65]. However, there are no data available yet to prove 
this suggestion. Further studies are necessary to 
elucidate the action of GLP-l(7-36) amide on hepatic 
glucose metabolism. 
GLP-I and stomach 
GLP-l(7-36) amide is a potent inhibitor of the penta- 
gastrin-induced gastric acid secretion in man. In low 
concentrations, such as 30 pmol/l [72] and 60 pmol/l 
1731, the peptide reduced pentagastrin-stimulated gas- 
tric acid secretion by 36% [72] and almost 50% [73], 
respectively and volume secretion by 33 and 36% [73]. 
Incubation of rat gastric glands or human gastric 
cancer cells with GLP-l(7-36) amide resulted in strong 
stimulation of cAMP production [25,73]. This latter 
finding is surprising since the enhancement of cAMP 
has an important role in the stimulation of acid 
secretion [74]. Interestingly, a very recent study 
revealed the existence of a single class of high affinity 
receptors for GLP-l(7-36) amide in rat gastric glands 
which were coupled to the adenylate cyclase system 
[25]. As long as these experiments have not been 
repeated with pure parietal cells the question is open as 
to whether or not the inhibitory effect of GLP-1 on the 
pentagastrin-stimulated acid secretion is mediated by 
CAMP. For the inhibitory effect of GLP-1(7-36) amide 
on acid secretion, alternatively an indirect effect 
possibly mediated by a regulation of additional hor- 
monal or paracrine mediators should be taken into 
account. 
Eissele, Koop & Arnold recently demonstrated a 
stimulatory effect on somatostatin release and an 
inhibition of gastrin secretion by GLP- l(7-36) amide 
in the isolated perfused rat stomach suggesting that the 
GLP- i(7-36) amide-induced inhibition of gastric acid 
secretion may be mediated by an enhanced somato- 
statin and/or a lowered gastrin release [75]. On the 
other hand, in pigs GLP-l(7-36) amide had no effect 
on somatostatin or gastrin secretion from the antrum 
or on somatostatin secretion from the nonantral 
stomach [42], suggesting that the inhibitory effect of 
GLP-1 on gastric acid secretion does not involve 
alterations of the somatostatin or gastrin level. These 
contradictory results could be due to species-specific 
differences in the regulation of acid secretion. Clearly, 
more work is necessary to understand fully the action 
of truncated GLP-1 on the stomach. However, the 
effects documented up to now strongly argue in favour 
of an enterogastrone-like activity of this peptide. 
GLP-1 and intestine 
Using polyclonal antibodies against GLP- 1 (1 -1 9) and 
GLP-I( 1-37) GLP-1-like immunoreactivity was iden- 
tified in colorectal enteroglucagon cells co-existing 
with glicentin-like immunoreactivity within single sec- 
retory granules [30,33]. Sequence determination of 
purified GLP-1 from rat, pig and human intestine 
revealed that the peptide is identical to proglucagon 
78-107 amide [15,16]. Investigations on the distri- 
bution of GLP- 1-like immunoreactivity in the gastro- 
intestinal tract showed highest concentrations in the 
terminal ileum and colon [16]. The GLP-l(7-36) amide 
content of the colon is increased in rats with strepto- 
zotocin-induced diabetes, which showed an increased 
food intake [16,76]. A similar increase of glucagon-like 
immunoreactivity has been shown in hypothermia- 
induced hyperphagia rats [77], so that the higher 
concentrations of GLP- 1 -like- and glucagon-like- 
immunoreactivity in the colon could be a consequence 
of an increased food intake. In rats with streptozo- 
tocin-induced diabetes, plasma levels and ileal peptide 
concentrations of glucagon-like immunoreactivity 
were elevated on days 8-22 of diabetes [76]. Pancreatic 
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glucagon-like immunoreactivity showed only a tran- 
sient rise on day 1 [76]. These differences between 
normal and diabetic rats were not due to an alteration 
of post-translational processing of proglucagon [76]. It 
has been speculated that peptides from proglucagon 
may exercise a trophic effect upon gastrointestinal 
mucosa 1781. However, no specific binding sites for lZsI- 
labelled GLP- l(7-36) amide could be detected on 
dispersed pig enterocytes [2 13. This finding suggests, 
but does not prove, that the truncated form of GLP-1 
is not a growth factor for the intestinal mucosa. 
GLP-1 and central nervous system 
GLP- 1 -like immunoreactivity has been identified in 
thalamus, hypothalamus, in the medullary nucleus 
tractus solitarius and in the dorsal and ventral parts of 
the medullary reticular nucleus [27,33,34,79-8 11. 
While proglucagon-mRNA from pancreas and intes- 
tine is identical, Han, Hynes, Jin, Towle, Lauder & 
Lund [34] demonstrated the presence of two different 
proglucagon mRNAs in rat brain. Cells in the medull- 
ary nucleus of the solitary tract hybridized to a 
synthetic oligonucleotide probe corresponding to nuc- 
leotide sequences in pancreatic proglucagon mRNA 
encoding GLP- 1, whereas cells in the hypothalamus 
did not. Polyadenylated RNAs from fetal rat brain 
contain two mRNAs. One mRNA of 1300 bases has 
the same size as pancreatic proglucagon mRNA while 
the second of 1500 bases may represent the hypothala- 
mic proglucagon mRNA. These data strongly suggest 
the presence of a proglucagon mRNA in hypothala- 
mus different from that in the pancreas and intestine 
[34]. However, studies with a rat pituitary tumour cell 
line (GHdC]), in which a metallothionein-glucagon 
fusion gene was introduced and expressed, showed 
that proglucagon is expressed in the brain in the same 
manner as in the intestine [82]. These results were 
confirmed by studies demonstrating the presence of 
GLP-l(7-36) amide in extracts of rat brain [27,79,81]. 
Furthermore, high affinity receptors for GLP-l(7- 
36) amide were identified in rat brain [27,83]. The 
distribution of receptors corresponds to the distribu- 
tion of GLP-1-like immunoreactivity, with the excep- 
tion of the pituitary gland. Thalamus, hypothalamus, 
pituitary gland and medulla oblongata were shown to 
be rich in GLP-I-binding sites [27]. Binding of the 
peptide resulted in an increased CAMP production in 
thalamus, hypothalamus and pituitary gland [27,84]. 
A recent study which determined the subcellular 
distribution of GLP- 1 -like immunoradioactivity 
revealed the presence of GLP-l(7-36) amide in the 
synaptosome fraction [SO]. It has been shown that 
GLP- 1(7-36) amide is released from hypothalamic 
tissue slices in a calcium-dependent manner by potas- 
sium stimulation [Sl]. It seems clear that GLP-l(7-36) 
amide has to be considered as a putative neurotrans- 
mitter. 
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